[1] Singal AK, Louvet A, Shah VH, et al. Grand rounds: Alcoholic hepatitis. J Hepatol, 2018, 69(2):534-543.
[2] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[3] Sehrawat TS, Liu M, Shah VH. The knowns and unknowns of treatment for alcoholic hepatitis. Lancet Gastroenterol Hepatol, 2020, 5(5):494-506.
[4] Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut, 2016, 65(5):830-839.
[5] van Rossen TM, van Beurden YH, Bogaards JA, et al. Fecal microbiota composition is a better predictor of recurrent Clostridioides difficile infection than clinical factors in a prospective, multicentre cohort study. BMC Infect Dis, 2024, 24(1):687.
[6] Chen Q, Fan Y, Zhang B, et al. Capsulized fecal microbiota transplantation induces remission in patients with ulcerative colitis by gut microbial colonization and metabolite regulation. Microbiol Spectr, 2023,11(3):e0415222.
[7] Madsen M, Kimer N, Bendtsen F, et al. Fecal microbiota transplantation inhepatic enc-ephalopathy: a systematic review. Scand J Gastroenterol, 2021, 56(5):560-569.
[8] 吴泽昂,王晓丽,王海霞. 论共生系统:肠道菌群和人类健康. 河南大学学报(自然科学版), 2019, 49(1):36-47.
[9] 孙玉,王惠惠,王晓宇,等.基于高通量测序技术分析肠道菌群在酒精性肝损伤小鼠中的变化. 安徽医科大学学报, 2022, 57(6):860-866.
[10] Fan Y, Ya EZ, Wang JD, et al. Comparison of microbial diversity and composition in jejunum and colon of the alcohol-dependent rats. J Microbiol Biotechnol, 2018, 28(11):1883-1895.
[11] Sakamaki A, Yokoyama K, Yamazaki F, et al. Small intestinal bacterial overgrowth D-iagnosed by a breath testand improved by rifaximin in a patient with hepatic encephalopathy and alcoholic liver cirrhosis. Intern Med, 2020,59(15):1849-1853.
[12] Kosnicki KL, Penprase JC, Cintora P, et al. Effects of moderate, voluntary ethanol con-sumption on the rat and human gut microbiome. Addict Biol, 2018,24(4):617-630.
[13] Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producingKlebsiella pneumoniae. Cell Metab, 2019,30(4):675-688,e7.
[14] Effenberger M, Waschina S, Bronowski C, et al. A gut bacterial signature in blood an-d liver tissue characterizescirrhosis and hepatocellular carcinoma. Hepatol Commun, 2023, 7(7):512-516.
[15] Kim SS, Eun JW, Cho HJ, et al. Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis. Aliment Pharmacol Ther, 2021,53(4):540-551.
[16] Duan Y, Chu H, Brandl K, et al. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat Commun, 2021,12(1):7172.
[17] Qian M, Liu J, Zhao D, et al. Aryl hydrocarbon receptor deficiency in intestinal epithelial cells aggravates alcohol-related liver disease. Cell Mol Gastroenterol Hepatol, 2022,13(1):233-256.
[18] Wang J, Wang P, Tian H, et al. Aryl hydrocarbon receptor/IL-22/Stat3 signaling pathw-ay is involved in the modulation of intestinal mucosa antimicrobial molecules by commen-sal microbiota inmice. Innate Immun, 2018,24(5):297-306.
[19] Yang AM, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest, 2017,127(7):2829-2841.
[20] Chu H, Duan Y, Lang S, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol, 2020,72(3):391-400.
[21] Zeng S, Hartmann P, Park M, et al. Malassezia restricta promotes alcohol-induced liverinjury. Hepatol Commun, 2023,7(2):e0029.
[22] Wang M, Feng X, Zhao Y, et al. Indole-3-acetamide from gut microbiota activated hepatic AhR and mediated the remission effect of Lactiplantibacillus plantarum P101 on alco-holic liver injury in mice. Food Funct, 2023,14(23):10535-10548.
[23] Bajaj JS, Gavis EA, Fagan A, et al. A randomized clinical trial of fecal Microbiota transplant for alcohol use disorder. Hepatology, 2021,73(5):1688-1700.
[24] Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplant-ation in steroid-ineligible severe alcoholic hepatitis: A pilot study. Clin Gastroenterol Hepatol, 2017,15(4):600-602.
[25] Philips CA, Ahamed R, Rajesh S, et al. Clinical outcomes and gut microbiota analysisof severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala. Gastroenterology Report, 2022,10:423-427.
[26] Situmorang JH, Chen MC, Kuo WW, et al. 9-POHSA prevents NF-kB activation and ameliorates LPS induced inflammation in rat hepatocytes. Lipids, 2023,58(5):241-249.
[27] Barreto CMA, do Valle EA, Moreira JPL, et al. Gut-related molecules as potential biomarkers in patients with decompensated cirrhosis. Ann Hepatol, 2024,12:101567.
[28] Han SH, Lee HD, Lee S, et al. Taraxacum coreanum Nakai extract attenuates lipopolysaccharide induced inflammatory responses and intestinal barrier dysfunction in Caco-2 cell-s. J Ethnopharmacol, 2024,319(Pt 1):117105.
[29] An L, Wirth U, Koch D, et al. The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases. J Gastrointest Surg, 2022,26(3):671-683.
[30] Kuo CH, Wu LL, Chen HP, et al. Direct effects of alcohol on gut epithelial barrier: Unraveling the disruption of physical and chemical barrier of the gut-epithelial barrier that compromises the host-microbiota interface upon alcohol exposure. J Gastroenterol Hepatol, 2024,39(7):1247-1255.
[31] Oami T, Yumoto T, Shimazui T, et al. Chronic ethanol use worsens gut permeability and alters tight junction expression in a murine sepsis model. Shock, 2023,60(2):280-290.
[32] Wang S, Liu J, Cheng D, et al. Bacillus subtilis pretreatment alleviates ethanol induce-d acute liver injury by regulating the Gut-liver axis in mice. Toxicology, 2023,488:153487.
[33] Teng T, Gao F, He W, et al. An early fecal microbiota transfer improves the intestinal conditions on microflora and immunoglobulin and antimicrobial peptides in piglets. J Agric Food Chem, 2020,68(17):4830-4843.
[34] Yang W, Ren D, Shao H, et al. Theabrownin from Fu Brick Tea improves ulcerative colitis by shaping the gut microbiota and modulating the tryptophan metabolism. J Agric Food Chem, 2023,71(6):2898-2913.
[35] Ki SH, Park O, Zheng M, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology, 2010,52(4):1291-300.
[36] Wei L, Pan Y, Guo Y, et al. Symbiotic combination of Akkermansia muciniphilaand inosine alleviates alcohol induced liver injury by modulating gut dysbiosis and immune res-ponses. Front Microbiol, 2024,15:1355225.
[37] Kim S, Lee Y, Kim Y, et al. Akkermansia muciniphila prevents fatty liver disease, decreases serum triglycerides, and maintains gHomeostasis. Appl Environ Microbiol,2020,86(7):e03004-eO3019.
[38] Shi Z, Lei H, Chen G, et al. Impaired intestinal Akkermansia muciniphila and aryl hydrocarbon receptor ligands contribute to nonalcoholic fatty liver disease in mice. mSystems,2021,6(1):e00985-eOO9920.
[39] Bu F, Ding Y, Chen T, et al. Total flavone of Abelmoschus Manihot improves colitis by promoting the growth of Akkermansia in mice. Sci Rep, 2021,11(1):20787.
[40] Tibbs TN, Lopez LR, Arthur JC. The influence of the microbiota on immune development, chronic inflammation, and cancer in the context of aging. Microb Cell, 2019,6(8):324-334.
[41] Zhou B, Yuan Y, Zhang S, et al. Intestinal flora and disease mutually shape the regional immune system in the intestinal tract. Front Immunol, 2020,11:575.
[42] Samuelson DR, Gu M, Shellito JE, et al. Intestinal microbial products from alcohol fed mice contribute to intestinal permeability and peripheral immune activation. Alcohol Clin Exp Res, 2019,43(10):2122-2133.
[43] Hendrikx T, Lang S, Rajcic D, et al. Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice. Gut, 2023,72(10):1959-1970.
[44] Zhu Y, Wang X, Zhu L, et al. Lactobacillus rhamnosus GG combined with inosine ameliorates alcohol-induced liver injury through regulation of intestinal barrier and Treg/Th1cells. Toxicol Appl Pharmacol, 2022,439:115923.
[45] Pande A, Sharma S, Khillan V, et al. Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial. Hepatol Int, 2023,17(1):249-261.
[46] Philips CA, Augustine P, Yerol PK, et al. Severe alcoholic hepatitis: current perspectives. Hepat Med, 2019,11:97-108.
[47] Philips CA, Phadke N, Ganesan K, et al. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol, 2018, 37(3):215-225.
[48] Philips CA, Phadke N, Ganesan K, et al. Healthy donor faecal transplant for corticoste-roid non-responsive severe alcoholic hepatitis. BMJ Case Rep, 2017,8:2017:bcr2017222310.
[49] Sood A, Singh A, Mahajan R, et al. Acceptability, tolerability, and safety of fecal mic-robiota transplantation in patients with active ulcerative colitis (AT&S Study). J Gastroenterol Hepatol, 2020,35(3):418-424.
[50] Ding X, Li Q, Li P, et al. Long-term safety and efficacy of fecal microbiota transplant in active ulcerative colitis. Drug Saf, 2019,42(7):869-880.
[51] Tun KM, Hong AS, Batra K, et al. A systematic review of the efficacy and safety of fecal microbiota transplantation in the treatment of hepatic encephalopathy andClostridioides difficile infection in patients with cirrhosis. Cureus, 2022,14(5):e25537. |
